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Introduction:  
Rudolf Kraus in 1897 described the precipitation reaction from his studies of anti-
cholera and anti-typhoid sera (1). Pauling in 1943 discussed the role of noncovalent  
forces (columbic, hydrogen bonding, hydrophobic, and Van Der Wall’s) involved in 
antibody-antigen reactions that contribute to precipitation (2). Reverberi and Reverberi 
described factors affecting antibody antigen reactions in terms of the Law of Mass 
action and equilibrium constants (3). Marack in1934 proposed the Lattice theory which 
states “Specific precipitation of antibodies and molecular antigens would result from the 
same mechanism if both antibody molecules and antigen molecules were multivalent” 
(4). Based on Marack’s theory, the antibody and its specific antigen must have at least 
two binding sites for effective cross linking to produce a visible lattice or precipitate 
(figure 1). 
Figure 1 
 
 
 
 
 
 
 
Alternatively, (univalent antibodies and univalent antigens), (multivalent antibodies and 
univalent antigens) and (univalent antibodies and multivalent antigens) will not result in 
extensive cross linking for lattice formation to occur.  In the late 1950s Soloman Berson 
and Rosalyn Yalow developed a very sensitive immunological assay that did not involve 
extensive cross linking of antibodies and antigens to form a visible precipitate for 
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antigen detection. The investigators labelled only antibody molecules with radioactive 
iodine for the detection of insulin (antigen) concentrations in circulation (5). This assay 
was called a Radioimmunoassay or RIA.  RIA is a member of a class of immunological 
assays that are called primary reactions.  As stated primary reactions do not involve 
multivalent antibodies or multivalent antigens for lattice formation and antigen detection.   
In primary reactions “visibility” occurs when the antibody is labelled with a radioactive 
element, an enzyme-fluorochrome or nanoparticles (quantum dots).  
Precipitation is a secondary reaction and is not as sensitive as primary reactions 
because very high concentrations of the antibody and antigen are needed to form a 
visible lattice for antigen or antibody detection. Primary reactions do not involve 
extensive cross linking of antibodies and antigens and therefore are excellent for the  
detection of trace levels of  antigens or  antibodies in experimental and clinical samples. 
The enzyme-linked immune sorbent assay (ELISA) was developed in 1971 to reduce 
the exposure to radioactive iodine. In the ELISA assay, the antibody is labelled with an 
enzyme-fluorochrome molecule (6). It should be clear that RIA, ELISA and quantum 
dots (QD) are not precipitation assays because optimal proportions of antibodies and 
antigen are not required for lattice formation. Quantum dots (QD) are fluorescence 
immunoassays that can amplify antigen detection at concentrations that are significantly 
lower than radioimmunoassay and ELISA.  It should be noted that, QD have been used 
with success in numerous biological systems as well as in the of study viral antigens (7).  
ELISAs can be classified as direct (primary antibody), indirect (primary and secondary 
antibodies), sandwich (two primary antibodies-first primary antibody serves to capture 
the antigen and the second primary antibody in labelled with an enzyme-fluorochrome 
to bind the captured antigen forming a “sandwich” for data collection (figure 2). Finally, 
the competitive assay involves two primary antibodies: unlabelled primary antibody 
competes with labelled primary antibody to bind a limited number of antigenic sites on a 
solid support. Additionally, the competitive ELISA can also involve labelled and 
unlabeled corticosterone (antigens) vying for limited number of sites on antibody 
molecules on a solid support shown below.  
The direct, indirect and sandwich ELISAs have positive slopes for the determination of 
antigen or antibody concentrations. Conversely the competitive ELISA has a negative 
slope for the determination of antigen or antibody concentration. Positive slopes occur 
when the increasing concentrations of antibody bind to increasing concentrations of 
antigenic sites on a solid support (figure 3). Negative slopes occur when labelled and 
unlabeled primary antibodies compete for limited number of antigenic sites on a solid 
support (figure 4). In this approach, secondary IgM antibodies with quantum dots will 
produce a positive slope when it binds to a primary IgG antibodies in our experimental 
design (figure 3).  
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Results: A modified approach of Bloch, Massa and Dill, involves the use of two different 
isotypes or classes of antibodies IgG and IgM, see Fig. 1 below.  Monomeric IgG has 
two identical heavy chains, two identical light chains and three constant regions on 
each heavy chain and one constant region on each light chain.   IgM has five 
identical monomers. Each monomer has two identical heavy chains, two identical light 
chains and four constant regions on each heavy chain and one constant region on 
each light chain. With respect to structure, it should be clear that the IgM cyclic 
pentameric is not a polymer of five identical IgG molecules (see figure 5 below) 
 
The variable regions on heavy and light chains defines the specificity of the antibody 
molecule for a given antigen.  It should be noted that both heavy chains and both light 
chains have identical sequences of amino acid residues in the variable regions in their 
respective chains.  
 
Competitive  ELISA 
For example, in the labelled figure of the IgG molecule (to the right) the amino acid 
residues on both heavy chains have the same exact sequence which we refer to 
“QEZGPSTWYV” or the blue color. The amino acid residues on both light chains have 
the same exact sequence that we have listed as “ARNDBCQEMFPS” or the red color 
(table 1). This illustrates that amino acid residues in the variable regions of heavy and 
light chains do not have identical sequences of amino acid residues to each other. 
Moreover it is important to note that each chain contributes 50% to the binding activity 
of the divalent antibody molecule. Finally, each antibody molecule to a different 
antigenic determinant will have its own unique amino acids residues in the variable 
regions on both heavy chains.  This argument also applies to the light chains as well.  
That is, the sequence of amino acid residues in the variable regions of both light chains 
are identical to each other but completely different from those in the variable regions for 
both heavy chains.  
 
Table 1  
  
 
 
 
 
  
Figure 5  
 A representation of IgG and IgM molecules. 
IgG is the primary antibody in our novel approach and IgM is the secondary antibody. 
By definition a primary antibody (IgG) has specificity for a given antigenic determinant. 
The secondary IgM antibody has specificity for a given primary (IgG) antibody (figure 6).  
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Any free antibody that has specificity and binds a given  
antigen is called a primary antibody.  Any free antibody that 
has specificity and bind the primary antibody is called a 
secondary antibody.  
In our experimental design, IgG has specificity and binds a 
given antigen. Therefore, the IgG is called a primary antibody. 
IgM has specificity and binds the primary IgG. Therefore, the 
IgM is called a secondary (IgM) antibody.   
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Researchers (6) have labelled IgM antibodies with quantum dot in their immunological 
assays.  However, in the article cited below the IgM was used as a primary antibody not 
a secondary antibody (8).  In our approach IgM is labelled with quantum dots and used 
as a secondary antibody to bind to primary IgG antibodies to amplify and enhance 
signal detection.   
How to produce a specific human secondary IgM 
Secondary IgM antibodies that are specific for IgG can be produced in at least two 
ways.  
Method 1.  Inject human IgG or its heavy chains into experimental animals such as 
rabbits and after 10 days to two weeks collect the serum samples and recover the IgM 
fraction and determine its titer. Label the recovered IgMs fraction with quantum dots 
using a published protocol (9).    
Method 2.  Dissociate IgM from rheumatoid factor (10), determine its titer and label the 
dissociated IgM with quantum dots (9,).  
 
 
 
Figure 7. Secondary human IgM Rheumatoid antibody binds primary IgG molecule. 
 
 
 
 
 
 
 
 
 
Investigators at Thermo Fisher Scientific have developed unique system for linking 
markers such as enzymes, quantum dots and number of ligands to antibody molecules 
for antigen detection. It is called siteclic antibody labelling system. Basically, it involves 
the chemical linking of a desired marker to side chain carbohydrates on antibodies 
molecules.  We have modified their method to label secondary IgM antibodies for use in 
our proposal because of the numerous number of carbohydrates that are found in cyclic 
pentameric IgM.  
 
Monomeric IgM has significantly more carbohydrates sites then monomeric IgG, 
ten vs two respectively (figures 8, 9). IgM exist predominately as a  cyclic 
pentamer with five monomer units with a total of 50 carbohydrates sites.  In our 
novel approach we can use the siteclick method to increase the covalent linkage 
of quantum dots to the carbohydrates sites in the IgM antibody molecule.  It is 
anticipated that this procedure will increase the sensitivity of our secondary IgM 
antibodies to bind any primary IgG antibodies and specific antigens in trace 
levels in clinical and experiment samples as detailed above. 
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  Discussion:  
In the early 1980s. Alexei Ekimov (11), working at the Vavilov State Optical Institute, in 
ST. Petersburg Russia investigated semiconductor nanocrystals, or colloidal quantum 
dots. Dr. Ekimov discovered the presence of nanosize crystals of these semiconductors 
in the glasses and that these nanocrystals could absorb light at much lower 
wavelengths than expected. Nanocrystals or quantum dots consist of 10-50 atoms and 
the nanocrystals can produce distinctive colors via fluorescence was determined by the 
size of the particles (12). This was an excellent discovery because microarrays or 
biochips with attached peptides for proteins analysis, drug screening, immunological 
assays, were usually visualized and analyzed using organic fluorescent dyes (8). 
Unfortunately the dyes had poor photo stability, and decreasing quantum yields upon 
conjugation to biomolecules. 
Based on numerous and documented successes with quantum dots, these procedures 
are replacing Enzyme linked immune assays (ELISA). It should be clear that our novel 
quantum dot assay employs secondary IgM antibodies to bind primary IgG molecules to 
amplify antigen detection. 
It should be clear that current Quantum dot (QD) assays do not use secondary IgM 
antibodies as the indicator system. They use primary labelled IgG (or IgM) as the 
indicator system.  Problems with this approach. For example, if 100 unrelated primary 
IgGs are involved in a hypothetical study, each of those 100 primary IgGs would have to 
be labelled with QD for specific detection of a given antigen.  In our approach, we do not 
label any of the 100 primary IgGs in the above hypothetical study.  We simplify the 
procedure by labelling secondary IgM antibodies with quantum dots to identify all of the 
100 primary IgG antibody molecules. This works because the secondary IgM will bind to 
sites that are common to all IgG antibody molecules 
 
Procedure for the hypothetical study.  
Add each of the100 unique and unrelated antigens to 100 separate labelled wells in 
microtiter plates for incubation with its specific primary IgG. After the incubation period 
rinse each well to remove unreacted primary IgG. Now add the labelled secondary IgM 
with quantum dots to each of the 100 wells for the second incubation period. Finally, 
rinse the wells to remove unreacted secondary IgM labelled antibodies and analyze the 
data. It should be clear that the secondary IgM will recognize the 100 primary IgGs in 
the separate wells in the microtiter plates that are bound to each specific antigen. As 
stated above this works because the secondary IgM is bind to sites that are common to 
all IgG molecules. Therefore, secondary IgM “does not care” what specific antigens 
primary IgGs recognizes -all that concerns the secondary IgM is the presence of 
common sites or epitopes on all primary IgG antibodies for secondary IgM to bind. 
However, if the primary IgG antibodies did not recognize the antigen in the first 
incubation step, the primary IgG will not be bound and would be washed away when the 
wells are rinsed. Therefore, when the secondary IgM is added for the second incubation 
step- it cannot bind because the primary IgG antibodies were not present. Finally, the 
wells are washed to remove unreacted secondary IgM before data collection.   
 
Malito, Carfi and Bottomley have written an excellent review on the use of protein 
crystallography in vaccine research development.  Additionally, they described how 
structural information and protein engineering can lead to the development of antigens  
that are safe, protective and easy to develop(13).  The kernel energy method (KEM) or 
quantum crystallography (14-16) in which Lou Massa is a co-developer can apply 
quantum mechanics to study peptides with the best negative interaction energies as 
potential candidates for vaccine development. The kernel energy method (KEM) carried 
to second order has been used to calculate the quantum mechanical ab initio molecular 
energy of peptides, protein (insulin and collagen), DNA, and RNA and the interaction of 
drugs with their biochemical molecular targets (17).  The novel quantum dot approach in 
this proposal will allow us to monitor antibody response to the best peptides from 
bacterial and viral pathogens that were chosen from KEM calculations.  Our 
immunological assay involving secondary IgM antibodies amplifies antigen and antibody 
detection and reduces the cost and time for investigators in the laboratory to obtain 
such data. Finally, we are seeking collaboration with technology companies to market 
our unique approach. 
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